Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glibenclamide - Biogen

Next Previous
Drug Profile

Glibenclamide - Biogen

Alternative Names: BIIB 093; CIRARA; Diabeta; Glybenclamide; Glyburide for injection; RP-1127

Latest Information Update: 04 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Remedy Pharmaceuticals
  • Developer Biogen; Ohio State University; Remedy Pharmaceuticals
  • Class Antihyperglycaemics; Benzamides; Small molecules; Sulfonylureas; Vascular disorder therapies
  • Mechanism of Action ABCC8 protein antagonists; TRPM4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries; Stroke
  • New Molecular Entity No

Highest Development Phases

  • Phase III Stroke
  • Phase II Brain injuries; Spinal cord injuries

Most Recent Events

  • 25 Aug 2023 Biogen terminates a phase-III trial in Stroke in Hungary, the US, Australia, Belgium, Brazil, Canada, China, Croatia, Czech Republic, Denmark, Finland, France, Germany, Israel, Italy, Japan, South Korea, Lithuania, Portugal, Russia, Spain, Switzerland, Taiwan, and the UK (IV, Injection) due to operational challenges and other strategic considerations (NCT02864953) (EudraCT2017-004854-41)
  • 10 Aug 2023 Biogen terminates a phase-II ASTRAL trial in Brain injuries in Spain, Japan, Italy, Germany, France, Israel, USA (IV) due to strategic considerations, not for efficacy or safety reasons (NCT03954041)
  • 01 May 2023 Biogen terminates asset purchase agreement with Remedy Pharmaceuticals for BIIB 093
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top